Background: Laparoscopic adjustable gastric banding (LAGB) is an effective bariatric procedure with low morbidity and mortality. Unfortunately, it is fraught with high failure rates in long-term follow-up. Laparoscopic sleeve gastrectomy (LSG) is an emerging procedure, quickly gaining momentum in the arsenal of bariatric practice as a first step toward gastric bypass/biliopancreatic diversion or as a stand-alone operation. Recently, it has been described as a revisional option for previous bariatric surgery failures. We report our early experience with LSG as a revisional procedure for failed LAGB.
Methods: From January 2007 to April 2010, 46 patients, who had undergone LAGB, underwent LSG. Patient demographics, reason for band removal, interval between removal and LSG, operative times, estimated blood loss, complications, length of hospital stay, and percent of excess weight loss were collected.
Results: Of the 46 patients, 20 (43%) had their bands removed before LSG (median time interval, 2 years; range, 2 months to 9 years); the rest had concomitant band removal and LSG. Twelve patients were men (26%). Mean age and BMI were 40 (range, 20-60) years and 43.1 kg/m(2) (range, 33-57), respectively. In two cases, surgery was converted to an open procedure due to extensive adhesions related to previous surgeries. Median operative time, estimated blood loss, and length of hospital stay were 118 (range, 70-250) minutes, 41 (range, 5-600) ml, and 3 (range, 1-100) days, respectively. Major morbidity was encountered in three patients (6%; leak in 2 and bleeding in 1). There were no mortalities. Mean follow-up time for our cohort is 17 (range, 1-39) months. Percent of excess weight loss at 2, 6, 12, 24, and 36 months was 24, 37, 53, 51, and 48%, respectively.
Conclusions: Our results suggest that LSG is safe, feasible, and effective as a revisional procedure for failed LAGB and can be considered as an appealing option in these cases. Larger series and longer follow-up are needed to confirm this.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00464-011-1615-3 | DOI Listing |
Pan Afr Med J
January 2025
Département de Chirurgie et Spécialités, Faculté de Médecine et des Sciences Biomédicales de l'Université de Yaoundé I, Yaoundé, Cameroun.
While the prevalence of overweight and obesity is rising in Africa, the practice of bariatric surgery remains limited in our country, Cameroon. Weight loss outcomes following sleeve gastrectomy (SG), the most widely used bariatric surgery technique worldwide, have not yet been studied in our context. The medical records of all patients who underwent SG in our surgery department between January 1, 2016, and September 30, 2020, were reviewed retrospectively.
View Article and Find Full Text PDFJ Med Case Rep
January 2025
Department of Surgery, Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles and Keck School of Medicine of USC, Los Angeles, CA, USA.
Background: Classic congenital adrenal hyperplasia, primarily due to 21-hydroxylase deficiency, leads to impaired cortisol and aldosterone production and excess adrenal androgens. Lifelong glucocorticoid therapy is required, often necessitating supraphysiological doses in youth to manage androgen excess and growth acceleration. These patients experience higher obesity rates, hypertension, and glucose metabolism issues, complicating long-term health management.
View Article and Find Full Text PDFJ Clin Med
January 2025
Division of General Surgery, Tel Aviv Sourasky Medical Center, 6 Weizman St., Tel Aviv 6423906, Israel.
: Metabolic and bariatric surgery (MBS) is a well-established treatment for severe obesity, yet its effects in patients with inflammatory bowel disease (IBD) are not well understood. MBS in this population presents unique challenges, including the potential for exacerbating inflammatory disease activity and causing complications such as malnutrition and medication malabsorption. This study aims to assess the long-term outcomes of MBS in IBD patients, focusing on both metabolic outcomes and its impact on the course of IBD.
View Article and Find Full Text PDFMedicina (Kaunas)
December 2024
Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
Metabolic and bariatric surgery (MBS) is an effective intervention for patients with severe obesity and metabolic comorbidities, particularly when non-surgical weight loss methods prove insufficient. MBS has shown significant potential for improving quality of life and metabolic health outcomes in individuals with obesity, yet it carries inherent risks. Although these procedures offer a multifaceted approach to obesity treatment and its clinical advantages are well-documented, the limited understanding of its long-term outcomes and the role of multidisciplinary care pose challenges.
View Article and Find Full Text PDFOrthopadie (Heidelb)
January 2025
Klinikum Dortmund, Klinik für Chirurgie, Klinikum der Universität Witten/Herdecke, Beurhausstraße 40, 44137, Dortmund, Deutschland.
Background: Over the past 20 years, surgical treatment of obesity, or metabolic surgery, has established itself as an extremely efficient and sustainable therapy for treating severely overweight patients. Compared to non-surgical weight reduction procedures, surgical techniques have been shown to be superior in all studies, both in terms of short-term and long-term effectiveness. On the other hand, the invasiveness of the procedures is something that many patients view critically.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!